静脉与口服β受体阻滞剂在B型主动脉夹层修复术中的作用
本研究基于Premier医疗数据库(2009年6月至2015年3月),纳入接受开放手术或腔内修复的非创伤性B型主动脉夹层患者1752例,分析口服及静脉β受体阻滞剂与院内结局的关联。结果显示口服β受体阻滞剂与较低的院内死亡和卒中风险独立相关,静脉美托洛尔是唯一与死亡率降低相关的静脉β受体阻滞剂。
要点
- 口服β受体阻滞剂与修复术后院内死亡风险降低独立相关(aRR 0.53)。
- 口服β受体阻滞剂与卒中风险降低独立相关(aRR 0.46)。
- 静脉美托洛尔是唯一与死亡率降低相关的静脉β受体阻滞剂(aRR 0.62)。
核心结论
- 口服β受体阻滞剂与TBAD修复术后院内死亡和卒中风险显著降低相关。
- 静脉美托洛尔是唯一与生存改善相关的静脉β受体阻滞剂类型。
研究设计与样本
- 回顾性队列研究,查询Premier医疗数据库(2009年6月至2015年3月)。
- 通过ICD-9-CM诊断和操作代码识别非创伤性孤立性TBAD患者,排除TAAD。
- 共1752例接受开放手术(54.3%)或腔内修复(45.7%)。
主要发现
- 开放手术组口服BB使用率16.0%,腔内修复组56.4%。
- 开放手术组BB患者死亡率7.9% vs 非BB患者16.7%(P=0.006);腔内修复组3.3% vs 9.2%(P<0.001)。
- 口服BB与死亡率降低独立相关(aRR 0.53,95%CI 0.32-0.90,P≤0.02)。
- 口服BB与卒中风险降低独立相关(aRR 0.46,95%CI 0.25-0.87,P≤0.02)。
- 静脉美托洛尔与死亡率降低相关(aRR 0.62,95%CI 0.46-0.85,P=0.003)。
关键数值与推荐
- 口服BB组调整后死亡风险aRR 0.53(95%CI 0.32-0.90)。
- 口服BB组调整后卒中风险aRR 0.46(95%CI 0.25-0.87)。
- 静脉美托洛尔调整后死亡风险aRR 0.62(95%CI 0.46-0.85)。
- 静脉美托洛尔剂量≤10 mg与死亡率降低相关:6.3%(3.0-9.5%)vs 无IV BB组8.1%(4.6-11.6%)。
临床怎么用
- 在TBAD患者修复围术期,应考虑使用口服β受体阻滞剂以降低院内死亡和卒中风险。
- 若需静脉β受体阻滞剂,美托洛尔可能是优先选择,尤其剂量≤10 mg时与死亡率降低相关。
局限性
- β受体阻滞剂对TBAD长期手术结局的影响尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Beta-blockers have become the cornerstone for medical management in patients with chronic type B aortic dissection (TBAD). However, the effect of being on and/or receiving intravenous beta-blockers during hospitalization on outcomes of surgical repair of TBAD is not fully described. We sought to investigate this association during open surgical repair (OSR) and endovascular (Endo) intervention for nontraumatic TBAD. METHODS: The Premier Healthcare Database was inquired (June/2009-March/2015). Patients with nontraumatic isolated TBAD were identified via ICD-9-CM diagnosis and procedural codes. Patients with codes that indicated TAAD were excluded. In-hospital mortality, cardiac complications (CHF, MI, arrythmia) and stroke were evaluated. Log binomial regression analyses with bootstrapping were performed to assess the relative risk of adverse outcomes. RESULTS: A total of 1,752 were admitted for OSR (54.3%) and Endo (45.7%) TBAD repair. Use of oral beta blocker (BB) was 16.0% in OSR and 56.4% in Endo groups. In each arm, patients on BB were more likely to be diabetic, on aspirin or statin and more likely to receive additional IV BB than nonBB patients. There was no significant difference in age, sex, race, or prior history of CHF between BB and nonBB groups. Mortality was proportionally lower in patients on BB in OSR group (7.9% vs. 16.7%; P = 0.006) and Endo (3.3% vs. 9.2%; P < 0.001). The adjusted relative risk for mortality and stroke were significantly lower in oral BB recipients compared with none [aRR (95% CI): 0.53 (0.32-0.90) and 0.46 (0.25-0.87); both P ≤ 0.02]. IV metoprolol was the only IV BB that reduced mortality [aRR (95% CI): 0.62 (0.46-0.85); P = 0.003]. A dose of ≤10 mg was associated with significant mortality reduction: 6.3% (3.0-9.5%) compared with 8.1% (4.6-11.6%) in no IV BB group. Cardiac complications were not affected by BB use. CONCLUSIONS: For patients with nontraumatic TBAD, use of oral BB was associated with significant protection against in-hospital mortality and stroke following repair. Metoprolol was the only Intravenous BB type associated with improved survival. Further research is warranted to elucidate the effect of beta-blockers on the long-term surgical outcomes of TBAD.
引用
- Nejim B, Mathlouthi A, Naazie I, et al. The Effect of Intravenous and Oral Beta-Blocker Use in Patients with Type B Thoracic Aortic Dissection. Ann Vasc Surg. 2021. PMID: 34656722. doi:10.1016/j.avsg.2021.07.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。